Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803

Kimmie Ng; Shuji Ogino; Jeffrey A. Meyerhardt; Jennifer A. Chan; Andrew T. Chan; Donna Niedzwiecki; Donna Hollis; Leonard B. Saltz; Robert J. Mayer; Al B. Benson; Paul L. Schaefer; Renaud Whittom; Alexander Hantel; Richard M. Goldberg; Monica M. Bertagnolli; Alan P. Venook; Charles S. Fuchs

doi:10.1093/jnci/djr307

Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803

Kimmie Ng^*, Shuji Ogino, Jeffrey A. Meyerhardt, Jennifer A. Chan, Andrew T. Chan, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Al B. Benson, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Monica M. Bertagnolli, Alan P. Venook, Charles S. Fuchs

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

70 Scopus citations

Abstract

Background Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown. Methods We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan-Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided. Results Among 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (Ptrend =. 63,. 63, and. 59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (Pinteraction =. 84,. 67, and. 98 for DFS, RFS, and OS, respectively). Conclusion Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status.

Original language	English (US)
Pages (from-to)	1540-1551
Number of pages	12
Journal	Journal of the National Cancer Institute
Volume	103
Issue number	20
DOIs	https://doi.org/10.1093/jnci/djr307
State	Published - Oct 19 2011

Funding

This work was supported by the National Cancer Institute at the National Institutes of Health (P50CA127003 and T32CA009001-34 to K.N.); American Society of Clinical Oncology Career Development Award (K.N.); The Charles A. King Trust Postdoctoral Fellowship Award, Bank of America, Co-Trustee (K.N.); as well as by Pharmacia & Upjohn Company (now Pfizer Oncology). The research for CALGB 89803 was also supported, in part, by grants from the National Cancer Institute at the National Institutes of Health (CA31946) to the Cancer and Leukemia Group B (Richard L. Schilsky, Chairman) and to the CALGB Statistical Center (Stephen George, CA33601).

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jnci/djr307

Cite this

Ng, K., Ogino, S., Meyerhardt, J. A., Chan, J. A., Chan, A. T., Niedzwiecki, D., Hollis, D., Saltz, L. B., Mayer, R. J., Benson, A. B., Schaefer, P. L., Whittom, R., Hantel, A., Goldberg, R. M., Bertagnolli, M. M., Venook, A. P., & Fuchs, C. S. (2011). Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803. Journal of the National Cancer Institute, 103(20), 1540-1551. https://doi.org/10.1093/jnci/djr307

@article{6d645601a5314b95bdf93e81be2f9d00,

title = "Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803",

abstract = "Background Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown. Methods We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan-Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided. Results Among 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (Ptrend =. 63,. 63, and. 59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (Pinteraction =. 84,. 67, and. 98 for DFS, RFS, and OS, respectively). Conclusion Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status.",

author = "Kimmie Ng and Shuji Ogino and Meyerhardt, {Jeffrey A.} and Chan, {Jennifer A.} and Chan, {Andrew T.} and Donna Niedzwiecki and Donna Hollis and Saltz, {Leonard B.} and Mayer, {Robert J.} and Benson, {Al B.} and Schaefer, {Paul L.} and Renaud Whittom and Alexander Hantel and Goldberg, {Richard M.} and Bertagnolli, {Monica M.} and Venook, {Alan P.} and Fuchs, {Charles S.}",

note = "Funding Information: This work was supported by the National Cancer Institute at the National Institutes of Health (P50CA127003 and T32CA009001-34 to K.N.); American Society of Clinical Oncology Career Development Award (K.N.); The Charles A. King Trust Postdoctoral Fellowship Award, Bank of America, Co-Trustee (K.N.); as well as by Pharmacia & Upjohn Company (now Pfizer Oncology). The research for CALGB 89803 was also supported, in part, by grants from the National Cancer Institute at the National Institutes of Health (CA31946) to the Cancer and Leukemia Group B (Richard L. Schilsky, Chairman) and to the CALGB Statistical Center (Stephen George, CA33601).",

year = "2011",

month = oct,

day = "19",

doi = "10.1093/jnci/djr307",

language = "English (US)",

volume = "103",

pages = "1540--1551",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "20",

}

Ng, K, Ogino, S, Meyerhardt, JA, Chan, JA, Chan, AT, Niedzwiecki, D, Hollis, D, Saltz, LB, Mayer, RJ, Benson, AB, Schaefer, PL, Whittom, R, Hantel, A, Goldberg, RM, Bertagnolli, MM, Venook, AP & Fuchs, CS 2011, 'Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803', Journal of the National Cancer Institute, vol. 103, no. 20, pp. 1540-1551. https://doi.org/10.1093/jnci/djr307

TY - JOUR

T1 - Relationship between statin use and colon cancer recurrence and survival

T2 - Results from CALGB 89803

AU - Ng, Kimmie

AU - Ogino, Shuji

AU - Meyerhardt, Jeffrey A.

AU - Chan, Jennifer A.

AU - Chan, Andrew T.

AU - Niedzwiecki, Donna

AU - Hollis, Donna

AU - Saltz, Leonard B.

AU - Mayer, Robert J.

AU - Benson, Al B.

AU - Schaefer, Paul L.

AU - Whittom, Renaud

AU - Hantel, Alexander

AU - Goldberg, Richard M.

AU - Bertagnolli, Monica M.

AU - Venook, Alan P.

AU - Fuchs, Charles S.

N1 - Funding Information: This work was supported by the National Cancer Institute at the National Institutes of Health (P50CA127003 and T32CA009001-34 to K.N.); American Society of Clinical Oncology Career Development Award (K.N.); The Charles A. King Trust Postdoctoral Fellowship Award, Bank of America, Co-Trustee (K.N.); as well as by Pharmacia & Upjohn Company (now Pfizer Oncology). The research for CALGB 89803 was also supported, in part, by grants from the National Cancer Institute at the National Institutes of Health (CA31946) to the Cancer and Leukemia Group B (Richard L. Schilsky, Chairman) and to the CALGB Statistical Center (Stephen George, CA33601).

PY - 2011/10/19

Y1 - 2011/10/19

N2 - Background Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown. Methods We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan-Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided. Results Among 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (Ptrend =. 63,. 63, and. 59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (Pinteraction =. 84,. 67, and. 98 for DFS, RFS, and OS, respectively). Conclusion Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status.

AB - Background Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown. Methods We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan-Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided. Results Among 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (Ptrend =. 63,. 63, and. 59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (Pinteraction =. 84,. 67, and. 98 for DFS, RFS, and OS, respectively). Conclusion Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status.

UR - http://www.scopus.com/inward/record.url?scp=80052956941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052956941&partnerID=8YFLogxK

U2 - 10.1093/jnci/djr307

DO - 10.1093/jnci/djr307

M3 - Article

C2 - 21849660

AN - SCOPUS:80052956941

SN - 0027-8874

VL - 103

SP - 1540

EP - 1551

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 20

ER -

Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this